# **EAS 2025 Clinical and AI / ML Preview**

# **Download planner**



Accelerate your success

EAS 2025

2025



# EAS 2025 - General Overview



• Redefining Cardiovascular Prevention: A shift toward earlier and more aggressive management of lipid and inflammatory risk factors



• Integration of Cardiometabolic Care: A unified approach to managing dyslipidemia, type 2 diabetes, and obesity together



• Expansion of Non-Statin Therapies: Broad discussion on emerging LDL-C and Lp(a) lowering agents beyond traditional statins



 Translational Breakthroughs: Novel insights into how basic science findings are being rapidly translated into therapeutic candidates



 Focus on Residual Risk: Targeting inflammation, triglycerides, and lipoprotein(a) as key remaining drivers of CVD events



 Young Investigator Empowerment: Significant spotlight on earlycareer researchers in lipidomics, vascular biology, and metabolic disease



 Hybrid Global Access: Virtual and on-site participation expanded global engagement, fostering real-time worldwide collaboration



 Sustainability and Planetary Health: New emphasis on environmental impacts of cardiometabolic diseases and the role of planetary health in cardiovascular prevention





# EAS 2025 - Conference Themes (1/2)

- Targeting Lipoprotein(a) and Residual Cardiovascular Risk:
   Breakthroughs in RNA therapies aimed at Lp(a) reduction and residual risk mitigation
- Inflammation as a Therapeutic Target: Novel antiinflammatory agents explored beyond lipid-lowering, including NLRP3 and IL-1β inhibition



- Next-Generation Lipid-Lowering Therapies: Advances in oral PCSK9 inhibitors, ANGPTL3 inhibitors, and small interfering RNA approaches
- Cardiometabolic Disease Intersection: Integrated strategies addressing dyslipidemia, type 2 diabetes, NAFLD, and obesity as interlinked conditions
- Omics-Driven Precision Medicine: Application of lipidomics, proteomics, and polygenic risk scores to individualize prevention and treatment





# EAS 2025 - Conference Themes (2/2)

- Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Outcomes: Emerging data recognizing NAFLD as a major independent driver of cardiovascular disease
- Gut Microbiome and Atherosclerosis: Exploration of microbiome-derived metabolites influencing lipid metabolism and vascular inflammation



- Real-World Data and Pragmatic Cardiovascular Trials:
   Emphasis on integrating registry studies and real-world cohorts to validate clinical trial findings
- New Horizons in RNA and Gene Editing Therapies: Updates on CRISPR/Cas9 and antisense technologies for genetically inherited lipid disorders
- Diversity, Equity, and Representation in CVD Research: Strong calls for improving trial diversity across race, ethnicity, and sex to enhance generalizability







# Key Topics From Notable Presentations (1/4)



# Lipid-Lowering Therapies:

 The lipid-lowering landscape will evolve with siRNA therapies, novel PCSK9 inhibitors, and fixed-dose regimens driving personalized care. Real-world data will highlight treatment disparities and inform future guideline refinement



### **Atherosclerosis Pathogenesis and Therapy:**

 Atherosclerosis research will expand with novel immune, genetic, and metabolic insights, enhancing early detection and enabling targeted interventions to halt or reverse vascular disease progression



### Cardiovascular Risk and Treatment Strategies:

 Pharmacologic innovation in cardiovascular care will focus on SGLT2 inhibitors, RNA-based therapies, and lipoprotein(a) modulation, while genomic and sex-specific insights will drive individualized risk assessment and therapeutic precision



# Key Topics From Notable Presentations (2/4)



### Diabetes and Metabolic Syndrome:

 The conference will highlight the interplay between type 2 diabetes, obesity, and cardiovascular risk, showcasing data on arterial stiffness, plaque burden, liver dysfunction, and systemic inflammation. Novel biomarkers, real-world pharmacotherapies, and cell-based models will be presented to improve management of metabolic-associated diseases across diverse populations



### Clinical Trials and Real-World Studies:

 The conference will highlight early intensive lipid-lowering strategies, universal pediatric screening initiatives, and emerging biomarkers such as Lp(a), remnant cholesterol, and apolipoprotein variability to improve cardiovascular risk prediction and prevention outcomes across diverse populations





# Key Topics From Notable Presentations (3/4)



### • Genetics and Genomics:

 The conference will highlight innovative cardiovascular genetic research, featuring gene therapy, transcriptomics, and functional screening that refine diagnosis and introduce next-gen therapeutics for lipid and arterial disorders



#### Heart Disease and Heart Failure:

 Integrating biomarker discovery, immune modulation, and advanced imaging is transforming post-MI care by personalizing risk prediction and enabling targeted anti-inflammatory and metabolic interventions.



### **Cardiovascular Imaging and Diagnostics:**

 Cardiovascular diagnostics will be transformed by next-generation imaging modalities and functional assessments, offering early, noninvasive insights into disease activity, risk stratification, and treatment planning





# Key Topics From Notable Presentations (4/4)



#### **Inflammation and Immune Mechanisms:**

 Chronic vascular inflammation remains central to atherosclerosis, with new strategies focusing on immune modulation, lipid metabolism, and transcriptomic profiling to identify risk and guide anti-inflammatory therapies



### Other studies:

 Atherosclerosis management will shift toward precision interventions using gene-editing, proteomics, and targeted therapeutics, while clinical inertia and prevention gaps will be addressed by nationwide strategies and real-world trials





# Focus of Key Industry Sponsored Sessions at EAS 2025 (1/2)



### **Menarini Group:**

- Focus Areas: CETP Inhibition & Dyslipidemia Management
- Presentations will examine novel CETP inhibitors, their biological underpinnings, clinical potential in addressing cardiometabolic risk, and strategies to fill current gaps in lipid disorder management



### **Ultragenyx:**

- Focus Areas: Homozygous Familial Hypercholesterolaemia (HoFH) & Evinacumab Therapy
- Sessions will highlight diagnostic gaps in HoFH, real-world insights from the HICC registry, and comprehensive efficacy and safety data on evinacumab across pediatric and adult populations



#### **Amarin:**

- Focus Areas: Icosapent Ethyl (EPA) in Cardiovascular Risk Reduction
- Sessions will focus on clinical outcomes from REDUCE-IT, mechanistic insights into EPA's action, and how emerging evidence supports expanding guideline recommendations for icosapent ethyl in ASCVD prevention



2025



# Focus of Key Industry Sponsored Sessions at EAS 2025 (2/2)



### **Daiichi Sankyo:**

- Focus Areas: Lipid-Lowering Strategies & Real-World Evidence
- Sessions will address oral lipid-lowering therapies for high-risk patients, real-world data from the MILOS study, and the role of combination therapy in optimizing lipid management outcomes across diverse populations



#### **Chiesi:**

- Focus Areas: Comprehensive Management of HoFH in the UK
- Sessions will explore strategies for achieving LDL-C targets, optimizing long-term outcomes in adult HoFH, and utilizing real-world data to personalize care and reduce disease burden in the UK setting





Notable Presentations information at EAS 2025







Date	Author	Title
05 May 2025	Ekaterina Polyakova	ADDITIONAL CLINICAL POTENTIAL OF INCLISIRAN FOR PATIENTS WITH CHRONIC KIDNEY DISEASE
05 May 2025	Shoaib Afzal	LIPID-LOWERING TREATMENT IN WOMEN AND MEN WITH FAMILIAL HYPERCHOLESTEROLAEMIA FROM 1996 THROUGH 2021: A DANISH NATIONWIDE STUDY
05 May 2025	Ali Altebainawi	DO TWICE YEARLY INCLISIRAN VERSUS TWICE MONTHLY EVOLOCUMAB HAVE A HIGHER ADHERENCE RATE? A REAL-WORLD EVIDENCE FROM SAUDI ARABIA. (TWICE STUDY)
05 May 2025	Andrea D'Amuri	STATIN THERAPY IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: A POST-HOC ANALYSIS OF T.O.S.C.A. REGISTRY
05 May 2025	Inhar Esnaola	PLAQUE INSTABILITY AND STATIN THERAPY: A RETROSPECTIVE INSIGHT INTO CRYPTOGENIC ISCHEMIC STROKE
05 May 2025	Cristina Gavina	PREVALENCE OF STATIN INTOLERANCE IN A SELECTED POPULATION FROM INTEGRATED CARE UNITS:  AN EMULATION OF THE CLEAR OUTCOMES TRIAL
05 May 2025	Ruben Mijnster	VIEWS ON LIPID-LOWERING MEDICATION AND TREATMENT DECISIONS AMONG STATIN-INTOLERANT PATIENTS AND PATIENTS USING STATINS WHO RECEIVE PCSK9 INHIBITORS
05 May 2025	Matthew Waite	REAL-WORLD EXPERIENCE OF INCLISIRAN UP TO 27 MONTHS FROM INITIATION
05 May 2025	In-Ho Yang	CLINICAL OUTCOMES OF FIXED DOSE COMBINATION THERAPY OF LOW INTENSITY ROSUVASTATIN AND EZETIMIBE ON LIPID PROFILES IN HYPERCHOLESTEROLEMIA PATIENTS







Date	Author	Title
05 May 2025	Marta Biolo	REAL-WORLD EXPERIENCE OF EFFICACY AND SAFETY OF EVINACUMAB IN COMBINATION WITH LOMITAPIDE THERAPY IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
05 May 2025	Simone Mattivi	EFFICACY AND ADVERSE EVENTS OF THE USE OF BEMPEDOIC ACID IN A REAL-LIFE POPULATION
05 May 2025	Camilla Portinari	REAL-WORLD EXPERIENCE OF EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: CHECKMATE TO SEVERE HYPERCHOLESTEROLEMIA?
05 May 2025	Luigi Junior Valletta	THE EFFICACY OF BEMPEDOIC ACID THERAPY IN NO-TARGET PATIENTS TREATED WITH PCSK9  INHIBITORS
05 May 2025	Yusuf Ziya Sener	AN INSIGHT TO THE STATUS AND IMPACT OF STATIN USE IN CANCER PATIENTS WITH CORONARY  ARTERY DISEASE
05 May 2025	Jacob Christensen	COMPREHENSIVE LIPID AND METABOLITE PROFILING OF LONG-TERM SURVIVORS OF TYPE 1 DIABETES COMPARED TO HEALTHY CONTROLS: CROSS-SECTIONAL RESULTS FROM THE DIALONG STUDY IN NORWAY
05 May 2025	Deniz Demirci	COMPARISON OF THE RELATIONSHIP BETWEEN LIPID PARAMETERS AND AGE AT FIRST ACS IN BOTH GENDERS
05 May 2025	Florian Abel	SEBELIPASE ALFA TREATMENT RESULTS IN SUSTAINED IMPROVEMENT OF LIPID PARAMETERS IN SYMPTOMATIC PEDIATRIC AND ADULT LAL-D PATIENTS: LONGITUDINAL DATA FROM THE INTERNATIONAL LAL-D REGISTRY
05 May 2025	Maxima Mendez Castillo	FROM GENES TO HYPERCHOLESTEROLEMIA: THE BENEFITS OF INCLISIRAN THERAPY FOR GCKR POLYMORPHISMS IN A STATIN-INTOLERANT PATIENT – A CLINICAL CASE







Date	Author	Title
05 May 2025	Laila Tata	USING PRIMARY CARE DATA TO IDENTIFY SOCIODEMOGRAPHIC INEQUALITIES IN AGE AT STARTING LIPID-LOWERING THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA: A POPULATION-BASED ENGLAND-WIDE COHORT STUDY
05 May 2025	Laila Tata	EXPANDING THE UNITED KINGDOM PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA REGISTER FOR NEW EVIDENCE TO SUPPORT GUIDELINES ON LIPID LOWERING THERAPIES FOR CHILDREN WITH FH
05 May 2025	Rano Alieva	THE IMPACT OF ONE-YEAR INCLISIRAN TREATMENT ON ACHIEVING TARGET LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC CORONARY SYNDROME.
05 May 2025	Akshyaya Pradhan	UPFRONT HIGH-INTENSITY LIPID-LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE FOR UNCONTROLLED DYSLIPIDEMIA IN INDIAN ASCVD PATIENTS: A REAL-WORLD STUDY (HILL II - INDIA STUDY)
05 May 2025	Nadia Stancheva - Hristova	INCLISIRAN TREATMENT AT UMHAT "DR. GEORGI STRANSKI" - PLEVEN, BULGARIA
05 May 2025	Lorena Corso	EVOLOCUMAB: EVALUATION OF EFFICACY IN LDL CHOLESTEROL REDUCTION, CARDIOVASCULAR OUTCOMES AND TOLERABILITY IN REAL-WORLD PATIENTS
05 May 2025	Fadlina Chany Saputri	BRAZILIN MODULATES PCSK9 EXPRESSION VIA INHIBITION OF UPSTREAM TRANSCRIPTIONAL REGULATORS IN HEPG2 CELLS
05 May 2025	Raffaele Buganza	TREATMENT EFFECTS OF EZETIMIBE IN CHOLESTERYL ESTER STORAGE DISEASE
05 May 2025	Javier Ena	EFFECT OF INCLISIRAN ON LIPOPROTEIN(A) VALUES: A META-ANALYSIS







Date	Author	Title
05 May 2025	Gabriela Berg	COMPARISON OF DIFFERENT ESTIMATORS AND DIRECT HOMOGENEOUS ASSAY OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN A LARGE SOUTH AMERICAN POPULATION
05 May 2025	Javier Ena	REAL WORLD INCLISIRAN EFFICACY AND SAFETY: A META-ANALYSIS
05 May 2025	Iain Jones	QUANTITATIVE DATA COMPARING LDL RESULTS PRODUCED BY LIPID ULTRACENTRIFUGATION WITH THOSE CALCULATED BY THE SAMPSON EQUATION
05 May 2025	Derek Stouth	TREATING HYPERLIPIDEMIA BY TARGETING IP3R1 TO LOWER PCSK9 EXPRESSION AND SECRETION
05 May 2025	Martina Ugolotti	INVESTIGATING PCSK9 INHIBITION AS POTENTIAL STRATEGY IN ALZHEIMER'S DISEASE
05 May 2025	Simone Bini	ANGPTL3 AND PCSK9 LEVELS REGULATE THE CELLULAR BALANCE BETWEEN LIPOLYSIS AND LIPOGENESIS THROUGH STAT3
05 May 2025	Ozcan Basaran	GENDER DISPARITIES IN THE MANAGEMENT OF LIPID-LOWERING THERAPY FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE EPHESUS STUDY
05 May 2025	Marianne Klevmoen	WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA RECEIVE LESS LIPID-LOWERING TREATMENT AND ARE DIAGNOSED TOO LATE: RESULTS OF A SURVEY OF WOMEN WITH FH ACROSS THE WORLD
05 May 2025	Maria Boufounas	DISCREPANCIES IN LDL-C ESTIMATION: A COMPARISON OF FRIEDEWALD, SAMPSON, AND MARTIN-HOPKINS EQUATIONS IN HIGH-RISK POPULATIONS







Date	Author	Title
05 May 2025	Shaoshuai Mao	OPTIMIZATION OF EPIGENETIC REGULATORS FOR EFFICIENT AND LONG-LASTING SILENCING OF PCSK9 IN NON-HUMAN PRIMATES
05 May 2025	Thomas Vanassche	USAGE OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN BELGIAN PATIENTS WITH DYSLIPIDAEMIA: BASELINE CHARACTERISTICS AND 8-WEEK FOLLOW-UP DATA FROM THE MILOS STUDY
05 May 2025	Damiano D'Ardes	COULD DOCTORS REDUCE STATIN INTOLERANCE WITH A "DOCEBO" EFFECT?
05 May 2025	Alessandra Marengo	EARLY TNF-ALPHA LEVELS SUPPRESSION BY UPSTREAM EVOLOCUMAB USE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
05 May 2025	Laia Blanco-Casoliva	ATP-CITRATE LYASE INHIBITION BY BEMPEDOIC ACID PROTECTS AGAINST ABDOMINAL AORTIC  ANEURYSM
05 May 2025	Karen Hvid	ELEVATED REMNANT CHOLESTEROL CONFERS HIGH RISK OF ASCVD WITHOUT PROMPTING LIPID- LOWERING THERAPY: AN UNMET MEDICAL NEED
05 May 2025	Riccardo Mattia Ricciardi	SLCO1B1 MUTATION IS A PREDISPOSITION FOR STATIN INTOLERANCE INDEPENDENTLY FROM FH MUTATION IN PATIENT WITH HYPERCHOLESTEROLEMIA
05 May 2025	Rafael Graça	REGULATORY VARIANTS IN LDLR AND PCSK9 PROMOTER AND 5'UTR: INVESTIGATING THE IMPACT IN FAMILIAL HYPERCHOLESTEROLAEMIA
05 May 2025	Sining Xie	RISK OF ADVERSE EVENTS FOR STATINS, EZETIMIBE, BEMPEDOIC ACID, PCSK9 INHIBITORS, AND THEIR COMBINATIONS IN PATIENTS WITH DYSLIPIDEMIA: A NETWORK META-ANALYSIS








Date	Author	Title
05 May 2025	Kausik K. Ray	REAL WORLD INSIGHTS FROM THE UNITED KINGDOM ON 8-WEEK EFFECTIVENESS OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN PATIENTS WITH DYSLIPIDAEMIA
05 May 2025	Juan P. Nogueira	LIPID-LOWERING EFFICACY OF OBICETRAPIB: A COMPREHENSIVE SYSTEMATIC REVIEW AND META- ANALYSIS
05 May 2025	Maurizio Averna	EVALUATING DYSLIPIDAEMIA TREATMENT WITH BEMPEDOIC ACID AND EZETIMIBE OVER 8 WEEKS IN THE ITALIAN COHORT OF THE MILOS OBSERVATIONAL STUDY
05 May 2025	Klaus Parhofer	PERSISTENCE AND DETERMINANTS OF THERAPY DISCONTINUATION WITH PCSK9 MONOCLONAL ANTIBODIES IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK: PERI-DYS
05 May 2025	Thomas Stulnig	REAL-WORLD PROSPECTIVE DATA FROM AUSTRIA ON BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE FOR THE TREATMENT OF DYSLIPIDAEMIA
05 May 2025	Per Johanson	EFFICACY AND SAFETY OF AZD0780, AN ORAL SMALL MOLECULE PCSK9 INHIBITOR FOR TREATMENT OF HYPERCHOLESTEROLEMIA: RESULTS FROM A PH2B RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL
05 May 2025	Pam Taub	INCLISIRAN AS MONOTHERAPY COMPARED WITH PLACEBO OR EZETIMIBE IN PATIENTS AT LOW TO BORDERLINE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: RESULTS FROM THE VICTORION-MONO RANDOMIZED CLINICAL TRIAL
06 May 2025	Valeria Pecce	FLUORESCENT ORGANOID-BASED SYSTEM FOR MONITORING LONG-TERM TOLERANCE OF RNA-BASED THERAPIES: THE EXAMPLE OF ANGPTL3 AND PCSK9 SIRNAS ON HEPATIC ORGANOIDS.
06 May 2025	Dirk J. Blom	REAL-WORLD SAFETY AND EFFECTIVENESS OF LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA OVER TEN YEARS: DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER)







Date	Author	Title
06 May 2025	Jasmine Chebli	LONG TERM MONITORING OF PATIENTS WITH PERSISTENT CHYLOMICRONEMIA TREATED WITH LPL GENE REPLACEMENT THERAPY WHO SUBSEQUENTLY RECEIVED PRECISION ADD-ON THERAPIES
06 May 2025	Frederick J. Raal	EFFICACY OF LERODALCIBEP, A THIRD GENERATION PCSK9 INHIBITOR, ACCORDING TO FH GENOTYPE IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
06 May 2025	Elsa Franchi	IMPACT OF WESTERN DIET AND PCSK9 ON THE EXPRESSION OF AMYOTROPHIC LATERAL SCLEROSIS- PREDISPOSING GENES
06 May 2025	Jacob J. Christensen	COMPREHENSIVE LIPID AND METABOLITE PROFILING OF YOUTH WITH CHILDHOOD ONSET TYPE 1 DIABETES COMPARED TO HEALTHY CONTROLS: RESULTS FROM THE NORWEGIAN ACD STUDY
06 May 2025	Luís Masana-Marín	LOMITAPIDE IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) - ANALYSIS OF LONG-TERM (104-WEEK) SAFETY AND EFFICACY FROM THE APH-19 STUDY
07 May 2025	Frederick J. Raal	ZODASIRAN (ARO-ANG3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN LDL-CHOLESTEROL, APOLIPOPROTEIN B, AND ANGPTL3 IN PATIENTS WITH HOFH; GATEWAY FINAL RESULTS
07 May 2025	Borge G. Nordestgaard	LIPOPROTEIN(A) AND RECURRENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENTS BY SEX AND RACE/ETHNICITY AND USE OF LDL CHOLESTEROL LOWERING THERAPY: A COHORT STUDY FROM THE US FAMILY HEART DATABASE
07 May 2025	Ethan J. Weiss	A NOVEL ANGPTL4 INHIBITORY ANTIBODY SAFELY LOWERS PLASMA TRIGLYCERIDES AND REMNANT CHOLESTEROL IN HUMANS
07 May 2025	Steven E. Nissen	FIXED-DOSE COMBINATION OF OBICETRAPIB AND EZETIMIBE FOR LDL-C REDUCTION: A PHASE 3  RANDOMIZED TRIAL








Date	Author	Title
Virtual (On Demand)	Zeyad Bady	EFFICACY AND SAFETY OF LOMITAPIDE, A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR, IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
Virtual (On Demand)	Yuliia Kovalchuk	REGULAR DYNAMIC PHYSICAL ACTIVITY DURING THE OUTPATIENT PHASE OF CARDIAC REHABILITATION HELPS REDUCE PCSK9 LEVELS IN THE LONG TERM








Date	Author	Title
05 May 2025	Justus Wettich	MULTIMODAL DATASET INTEGRATION TO REDEFINE PLAQUE STABILITY IN HUMAN ATHEROSCLEROSIS
05 May 2025	Rinkoo Dalan	CAROTID ATHEROSCLEROSIS ASSOCIATES WITH INCIDENT CARDIOVASCULAR DISEASE IN MULTI- ETHNIC SINGAPORE
05 May 2025	Jakub Wojtacha	CIRCULATING MICRO-RNA IN THE ASSESSMENT OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
05 May 2025	Ying Jie Chee	HAND GRIP STRENGTH IS ASSOCIATED WITH ARTERIAL STIFFNESS IN INDIVIDUALS WITH  CARDIOMETABOLIC RISK FACTORS
05 May 2025	Shangmei Shirley Lin	ARTERIAL STIFFNESS IS INFLUENCED BY DIFFERENT CARDIOMETABOLIC RISK FACTORS
05 May 2025	Jana Petrkova	METHYLATION OF ADORA2A GENE IN PATIENTS WITH VASCULAR DISEASE (PILOT DATA)
05 May 2025	Yasunori Sawayama	LOW-DOSE ROSUVASTATIN PLUS EZETIMIBE VERSUS STANDARD-DOSE ROSUVASTATIN: THE EFFECT ON THE CAROTID ATHEROSCLEROSIS OF PATIENTS WITH HYPERCHOLESTEROLEMIA FOR TWO YEARS
05 May 2025	Oliver Heaney	MANIPULATION OF INTESTINAL MICROBIOTA AND POTENTIAL EFFECT ON EXPERIMENTAL ATHEROSCLEROSIS
05 May 2025	Ece Yurtseven	THE RELATIONSHIP OF HNP1-3, PCSK9, AND LP(A) WITH SUBCLINICAL ATHEROSCLEROSIS








Date	Author	Title
05 May 2025	Elsayed Farag	EGYPTIAN ASSOCIATION OF VASCULAR BIOLOGY AND ATHEROSCLEROSIS (EAVA) CONSENSUS ON THE USAGE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS
05 May 2025	Nemanja Vujić	CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY ON ATHEROSCLEROSIS DEVELOPMENT IN MICE
05 May 2025	Noemí Rotllan	LANDSCAPE OF LIPID UPTAKE FOR THE ESSENTIAL PROTEIN P116 OF THE HUMAN PATHOGEN MYCOPLASMA PNEUMONIAE: IMPLICATIONS FOR TROPISM TO ATHEROSCLEROTIC PLAQUES
05 May 2025	Maria Boufounas	MAXIMIZING THE POTENTIAL OF LP(A) IN VASCULAR RISK ASSESSMENT: AN OBSERVATIONAL ANALYSIS OF ITS UNDERUTILIZATION
05 May 2025	Ewelina Jozefczuk	SMOOTH MUSCLE CELL-DERIVED SPHINGOSINE KINASE 1 AS A KEY REGULATOR OF MYOGENIC TONE IN ANGIOTENSIN II-INDUCED HYPERTENSION
05 May 2025	Estelle Ollivier	ENDOTHELIAL P2X7 PROMOTES VENOUS THROMBOEMBOLISM
05 May 2025	Yumeng Han	TYROSINE KINASE INHIBITOR IMATINIB INDUCES LIPID ACCUMULATION VIA SREBP2 IN ENDOTHELIAL CELLS TO ENHANCE ATHEROSCLEROSIS
05 May 2025	Agnė Liuizė	A NEW BIOMARKER FOR ATHEROSCLEROSIS: THE LINK BETWEEN VIMENTIN AND DEGREE OF ATHEROSCLEROSIS DEVELOPMENT
05 May 2025	Piotr Szczepaniak	VASCULAR EFFECTS OF CHEMOTHERAPY IN BREAST CANCER: EXPLORING PROTECTIVE EFFECTS OF ESTROGENS IN PREMENOPAUSAL WOMEN







Date	Author	Title
05 May 2025	Joost Hoekstra	HUMAN VASCULAR SMOOTH MUSCLE CELL CALCIFICATION FUELS ISODGR PRODUCTION:  UNCOVERING A NEW MECHANISM IN ATHEROGENESIS.
05 May 2025	Nuriiat Efendieva	HIV-ASSOCIATED ATHEROSCLEROSIS. DATA RECEIVED BY OCT
05 May 2025	Elsayed Farag	PREDICTORS OF SUBCLINICAL ATHEROSCLEROSIS AND INCIPIENT MYOCARDIAL DYSFUNCTION IN ASYMPTOMATIC YOUNG HYPERTENSIVE SUBJECTS
05 May 2025	Adriana Puente Barragán	ATHEROGENIC DYSLIPIDEMIA AND MYOCARDIAL PERFUSION ABNORMALITIES IN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY: ¿DOES IT MATTER?.
05 May 2025	Tomohiko Asakawa	INTERLEUKIN-33 DEFICIENCY EXACERBATED ANGIOTENSIN II-INDUCED ABDOMINAL AORTIC ANEURYSMS BUT HAD NO EFFECT ON ANGIOTENSIN II-INDUCED ATHEROSCLEROSIS IN MALE APOLIPOPROTEIN E-DEFICIENT MICE.
05 May 2025	Peter Jones	SPLENIC TFH CELL LOCALISATION IN ATHEROSCLEROSIS
05 May 2025	Daryna Katashynska	THE ROLE OF IGM IN EFFEROCYTOSIS DURING ATHEROSCLEROSIS DEVELOPMENT
05 May 2025	Dalgisio Lecis	IDENTIFICATION OF A SELF-ANTIGEN SPECIFIC CD8+ T CELL POPULATION IN HUMAN CAROTID  ATHEROSCLEROTIC PLAQUES
05 May 2025	Aishvaryaa Prabhu	ROLE OF LYMPHOCYTE GPR18 SIGNALING IN ATHEROSCLEROSIS







Date	Author	Title
05 May 2025	Xueming Zhang	B CELL RESPONSES IN THE CONTEXT OF ATHEROSCLEROSIS: A REASSESSMENT
05 May 2025	Alessandro Scalia	DEVELOPMENT OF A MICROFLUIDIC MODEL TO MIMIC THE ATHEROSCLEROSIS INITIATION PROCESS  UNDER BREAST CANCER CELL EXPOSURE
05 May 2025	Lunnathaya Tapeng	HEALING ATHEROSCLEROTIC PLAQUES: PROSTACYCLIN DRIVES CYCLIC-AMP-MEDIATED HUMAN  MACROPHAGE GENE REGULATION
05 May 2025	Kristina Dimitrova	ATHEROSCLEROTIC PLAQUES FROM LEFT AND RIGHT CAROTID SHOW SIMILAR HISTOLOGICAL AND GENE EXPRESSION PROFILES







Date	Author	Title
05 May 2025	Dilafruz Akhmedova	EVALUATION OF THE EFFICACY OF TREATMENT USING SGLT2 INHIBITORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
05 May 2025	Amir Askarinejad	EFFICACY AND SAFETY PROFILE OF EMPAGLIFOZIN FOLLOWING ACUTE MYOCARDIAL INFARCTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
05 May 2025	Massimiliano Ruscica	RESULTS FROM AN ITALIAN SINGLE-CENTRE STUDY ON LP(A) LEVELS IN THE ACUTE CORONARY SYNDROME SETTING - INCREASED STEMI OCCURRENCE AND CORONARY COMPLEXITY
05 May 2025	Maurizio Panarelli	INCREASED LIPOPROTEIN (A) REQUESTING AS RESULTS OF CARDIOVASCULAR RISK GUIDELINES
05 May 2025	Rosalinda Posadas- Sánchez	MITOCHONDRIAL DNA COPY NUMBER (MTDNA-CN) IS ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE IN MEXICAN INDIVIDUALS. RESULTS OF THE GEA STUDY
05 May 2025	David Kallend	LERODALCIBEP AND ADJUDICATED CARDIOVASCULAR EVENTS IN A PRE-DEFINED POOLED ANALYSIS OF THREE LARGE LONG TERM PHASE III STUDIES
05 May 2025	Queenie Chan	GLOBAL BURDEN OF HIGH-RISK CARDIOVASCULAR PATIENTS WITHOUT PRIOR MYOCARDIAL INFARCTION OR STROKE: VESALIUS-REAL – PRELIMINARY RESULTS FROM UNITED KINGDOM
05 May 2025	Marte F. Van Der Bijl	SIMILAR EFFICACY OF CHRONIC PHARMACOLOGICAL TREATMENT IN WOMEN AND MEN WITH ACUTE CORONARY SYNDROME: A META-ANALYSIS AND META-REGRESSION
05 May 2025	James W. O'Brien	EXAMINING THE EFFECTS OF RITUXIMAB ON THE BCR REPERTOIRE FOLLOWING ANTERIOR ST ELEVATION MYOCARDIAL INFARCTION








Date	Author	Title
06 May 2025	Matteo Lemoli	PROTEINS PREDICTING ARTERIAL STIFFNESS AND HIGH BLOOD PRESSURE AND THEIR ASSOCIATION WITH CARDIOVASCULAR OUTCOMES: RESULTS FROM UK BIOBANK.
07 May 2025	Stephen J. Nicholls	SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS AT HIGH CARDIOVASCULAR RISK







Date	Author	Title
05 May 2025	Woohyeun Kim	EXPLORING THE LINK BETWEEN OBESITY AND ATHEROSCLEROTIC LIPID BURDEN: INSIGHTS FROM NIRS-IVUS AND BIA MEASUREMENTS
05 May 2025	Ying Jie Chee	NEUTROPHIL-LYMPHOCYTE RATIO IS ASSOCIATED WITH ALL-CAUSE MORTALITY AND INCIDENT CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS
05 May 2025	Rinkoo Dalan	MOLECULAR PHENOTYPING OF OXIDATIVE STRESS WITH POINT-OF-CARE MICROSCALE MAGNETIC RESONANCE (MNMR) SYSTEM ASSOCIATES WITH DIABETES STATUS AND VASCULAR FUNCTION IN A MULTI-ETHNIC COHORT FROM SINGAPORE
05 May 2025	Lamija Ferhatbegovic	PREVALENCE AND IMPACT OF ATHEROSCLEROTIC COMPLICATIONS IN PATIENTS WITH TYPE 2  DIABETES MELLITUS: A RETROSPECTIVE STUDY
05 May 2025	Romain Meer	ASSOCIATION BETWEEN CRURAL MEDIAL AND INTIMAL ARTERIAL CALCIFICATION PATTERNS WITH ARTERIAL STIFFNESS AND HFPEF IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS: THE CROSS-SECTIONAL EARLY-HFPEF STUDY
05 May 2025	Ekaterina Ogurtsova	ACTIVATED AND REGULATORY T-HELPERS AND BLOOD MONOCYTES IN PATIENTS WITH HFPEF AND  TYPE 2 DIABETES MELLITUS
05 May 2025	Sabrina Scilletta	SLEEP QUALITY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES: FROM GLYCEMIC CONTROL TO ANXIETY-DEPRESSIVE DISORDERS
05 May 2025	Pil Sang Song	DIABETES MELLITUS AND TRENDS IN SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION, 2011 TO 2020
05 May 2025	Joseph Blais	EFFECTIVENESS AND SAFETY OF STATINS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO PREDICTED 10-YEAR QRISK3 SCORE








Date	Author	Title
05 May 2025	Antonio Cutruzzolà	SGLT2-I IMPROVE MASLD, JUST LIKE GLP1-RA: A REAL-WORLD STUDY.
05 May 2025	Petr Nachtigal	MONOCLONAL ANTIBODY TARGETING ENDOGLIN PREVENTS LIVER SINUSOIDAL ENDOTHELIAL INFLAMMATION AND FIBROSIS PROGRESSION IN MASH
05 May 2025	Jae Hyoung Park	CORRELATION BETWEEN VISCERAL FAT AND CORONARY ARTERY CALCIUM IN METABOLIC SYNDROME  PATIENTS
05 May 2025	Meredith Donaldson	HOLISTIC MANAGEMENT OF MULTIMORBIDITY: A RETROSPECTIVE REVIEW OF COMORBID ASCVD, COPD, T2DM, AND CKD FROM 2020 TO 2024
05 May 2025	Djamshid Payziev	INFLUENCE OF LOW GLYCEMIC INDEX DIET ON BLOOD AGGREGATION STATE AND COAGULATION HEMOSTASIS IN PATIENTS WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE
05 May 2025	Francesca Schinzari	MIRABEGRON RELAXES ARTERIES OF HUMAN VISCERAL ADIPOSE TISSUE THROUGH ANTAGONISM OF ALPHA1-ADRENOCEPTORS
05 May 2025	Sevda Aygun	THE ROLE OF FLOW-MEDIATED DILATION IN ASSESSING CARDIOVASCULAR RISK AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A RETROSPECTIVE STUDY
05 May 2025	Alexandr Ceasovschih	LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN TYPE 2 DIABETES PATIENTS WITHOUT OPTIMAL GLYCEMIC CONTROL
05 May 2025	Ágnes Diószegi	RESULTS OF A SINGLE-CENTER RERTROSPECTIVE STUDY COMBYNING DMD TREATMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS








Date	Author	Title
05 May 2025	Emilie Gaillard	INDIVIDUALS WITH TYPE 2 DIABETES HAVE INCREASED CORONARY PLAQUE BURDEN AND PLAQUE PROGRESSION DURING 10-YEAR SERIAL CORONARY CT ANGIOGRAPHY FOLLOW-UP
05 May 2025	Festina Kuci	INVESTIGATING THE ROLE OF CELLULAR METABOLISM IN HEPATOCYTE AND ENTEROCYTE ON THE DEVELOPMENT OF STEATOSIS: FOCUS ON A BOTANICAL EXTRACT.
05 May 2025	Hajnalka Lőrincz	KALLISTATIN - A NEW BIOMARKER OF CARBOHYDRATE AND LIPID METABOLISM IN OBESITY AND TYPE 2 DIABETES
05 May 2025	Hidekatsu Yanai	EFFECTS OF ORAL SEMAGLUTIDE ON METABOLIC PARAMETERS AND RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES
05 May 2025	Rano Alieva	CARDIOMETABOLIC PROFILE IN PATIENTS WITH CORONARY ARTERY DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE:
05 May 2025	Alexandr Ceasovschih	THE IMPACT OF OBESITY ON PATIENTS WITH CARDIOVASCULAR DISEASES
05 May 2025	Wonjin Kim	IMPACT OF THE COVID-19 OUTBREAK ON THE OCCURRENCE OF METABOLIC SYNDROME ACCORDING TO THE METABOLIC SYNDROME SEVERITY SCORE
05 May 2025	Massimiliano Ruscica	LP(A) LEVELS IN INDIVIDUALS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE
05 May 2025	Mi-Seung Shin	FACTORS INFLUENCING THE PRACTICE OF A HEALTHY LIFESTYLE FOR MANAGING METABOLIC SYNDROME








Date	Author	Title
05 May 2025	Hyun-Jin Kim	SEX-SPECIFIC IMPACT OF THE COVID-19 PANDEMIC ON METABOLIC SYNDROME PREVALENCE
05 May 2025	Iryna Tverezovska	INFLUENCE OF SELENIUM SUPPLEMENTATION ON LIPID EXCHANGE IN PATIENTS WITH METABOLIC- ASSOCIATED LIVER DISEASE
05 May 2025	Jae Bin Seo	THE IMPACT OF ARTERIAL STIFFNESS ON THE PERFORMANCE OF PERCUTANEOUS CORONARY INTERVENTION ACCORDING TO THE OBESITY
05 May 2025	Jiyoon Park	BROWNING OF PERIVASCULAR ADIPOSE TISSUE DURING EARLY ATHEROSCLEROSIS PROGRESSION: A CONTRAST TO CLINICAL ATHEROSCLEROSIS
05 May 2025	Laura Comi	METABOLOMIC AND FUNCTIONAL CHARACTERIZATION OF HUMAN CELL MODELS TO INVESTIGATE THE PATHOGENETIC MECHANISMS UNDERLYING OBESITY AND METABOLIC DYSFUNCTION- ASSOCIATED STEATOTIC LIVER DISEASE
07 May 2025	Stefano Romeo	CLINICAL STAGING TO GUIDE ACTIONABLE MANAGEMENT OF SYSTEMIC METABOLIC DISORDERS AND THEIR SEQUELAE: A EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS STATEMENT
Virtual (On Demand)	Zeyad Bady	EFFICACY OF PHARMACOTHERAPIES ON PEDIATRIC PATIENTS WITH METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS








Date	Author	Title
05 May 2025	Fabian Demeure	OPTIMISING LIPID MANAGEMENT IN VERY HIGH-RISK PATIENTS: A RETROSPECTIVE STUDY ON THE IMPACT OF LIPIDOLOGIST-LED CARE
05 May 2025	Renata Fasano	A REAL-WORLD PROTOCOL OF EARLY USE OF TRIPLE LIPID LOWERING THERAPY IN ACS
05 May 2025	Seung Hwan Han	NON-DIABETIC OVERWEIGHT/OBESE PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION HAVE IMPROVED CLINICAL OUTCOMES: A 10-YEAR LONGITUDINAL FOLLOW-UP STUDY
05 May 2025	Nitish Behary Paray	A META-ANALYSIS EVALUATING DIASTOLIC DYSFUNCTION IN PATIENTS WITH SARCOIDOSIS USING TRANSMITRAL VELOCITY PARAMETERS
05 May 2025	Caroline Marchand	IMPACTS OF A 12-WEEK CARDIOVASCULAR REHABILITATION PROGRAM ON LIMB HEMODYNAMICS, MOBILITY AND QUALITY OF LIFE IN PATIENTS WITH SYMPTOMATIC ATHEROSCLEROTIC DISEASE: A PROSPECTIVE COHORT STUDY
05 May 2025	Talal Warsi	AORTIC VALVE REPLACEMENT (AVR) VERSUS CONSERVATIVE CARE IN PATIENTS WITH ASYMPTOMATIC AORTIC STENOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
05 May 2025	Kevin Jon Williams	RATES OF ATHEROSCLEROTIC CARDIOVASCULAR EVENTS AND THEIR MANAGEMENT IN A LONGITUDINAL COHORT OF DERMATOMYOSITIS PATIENTS WITH SKIN INVOLVEMENT
05 May 2025	Marco Allegra	LIPID LOWERING THERAPY AND CARDIOVASCULAR PREVENTION: A RETROSPECTIVE OBSERVATION AT A SPOKE EMERGENCY DEPARTMENT IN PADUA PROVINCE.
05 May 2025	Jaime Garcia De Tena	HOSPITAL ADMISSION FOR ANY CAUSE AS AN OPPORTUNITY TO IMPROVE LIPID CONTROL IN PATIENTS AT MODERATE TO VERY HIGH CARDIOVASCULAR RISK: A CROSS-SECTIONAL OBSERVATIONAL STUDY








Date	Author	Title
05 May 2025	Mayo Shimoyama	CAN SELF-REPORTED LAUGHTER AND STRESS SCORES INFLUENCE COGNITIVE FUNCTION IN A JAPANESE GENERAL POPULATION? THE TANUSHIMARU STUDY
05 May 2025	Felix Fath	CHANGES AND FINDINGS IN REGISTRY PATIENTS AT FOLLOW-UP ASSESSMENT AT CARE HIGH
05 May 2025	Rong Xian Chen	EXPLORING GENDER DIFFERENCES IN THE ASSOCIATION OF HYPERTENSION, HYPERLIPIDEMIA, AND HYPERGLYCEMIA WITH PHYSICAL ACTIVITY IN TAIWAN: A POPULATION-BASED CROSS-SECTIONAL STUDY
05 May 2025	Arrigo Cicero	RELIABILITY OF DIFFERENT PLASMA APOLIPOPROTEIN B LEVELS ESTIMATING FORMULAS IN A LARGE COHORT OF SOUTH-EUROPEAN SUBJECTS
05 May 2025	Mohammad Abusido	ABSENCE OF STANDARD MODIFIABLE RISK FACTORS IN OBESE AND OVERWEIGHT INDIVIDUALS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A MIDDLE EASTERN COHORT STUDY
05 May 2025	Natalia Etcheverry	EVALUATION OF UNIVERSAL DYSLIPIDEMIA SCREENING IN ARGENTINEAN PEDIATRICS THROUGH ANONYMOUS SELF-COMPLETED ONLINE SURVEY
05 May 2025	Akshyaya Pradhan	A RETROSPECTIVE OBSERVATIONAL STUDY ON THE USAGE PATTERNS AND SAFETY OF FIXED-DOSE COMBINATION OF ROSUVASTATIN, ASPIRIN AND CLOPIDOGREL IN INDIAN PATIENTS WITH ACUTE CORONARY SYNDROME
05 May 2025	Katarina Raslova	AN OBSERVATIONAL STUDY LEVERAGING MANDATORY UNIVERSAL PEDIATRIC TOTAL CHOLESTEROL SCREENING IN SLOVAKIA
05 May 2025	Aris Agouridis	LIPOPROTEIN (A) AND PSORIASIS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS







Date	Author	Title
05 May 2025	Pimjai Anthanont	PREVALENCE OF HIGH PLASMA LIPOPROTEIN(A) IN OBSTRUCTIVE CORONARY ARTERY DISEASE PATIENTS WITH WELL-CONTROLLED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: RETROSPECTIVE STUDY
05 May 2025	Janeni Jeevanathan	SEX DIFFERENCES OF LIPOPROTEIN(A) IN INDIVIDUALS AGED 18-90 YEARS - A NATIONWIDE STUDY  OF 149,000 INDIVIDUALS
05 May 2025	Byung Jin Kim	IMPACT OF COTININE-VERIFIED SMOKING STATUS ON CHANGES IN LIPOPROTEIN(A) LEVELS: FROM A LONGITUDINAL STUDY
05 May 2025	Maurizio Panarelli	LIPOPROTEIN (A) IN A COHORT PRESENTING WITH FEATURE OF FAMILIAL HYPERCHOLESTEROLAEMIA BUT NEGATIVE GENETICS
05 May 2025	Laura Volpi	EVINACUMAB TREATMENT OF CARDIOVASCULAR HIGH-RISK PATIENTS IN A REAL-WORLD SETTING
05 May 2025	Frank Annie	IMPACT OF PREOPERATIVE HEARTFLOW ASSESSMENT ON GRAFT FAILURE RATES FOLLOWING CORONARY ARTERY BYPASS GRAFTING: A RETROSPECTIVE COHORT STUDY
05 May 2025	Pekka Karhunen	PROTEOMICS ANALYSIS REVEALS ORAL BACTERIAL PROTEINS IN CORONARY CALCIFIED ATHEROMAS.  TAMPERE SUDDEN DEATH STUDY
05 May 2025	Yume Nohara-Shitama	COMBINED SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND HIGH-SENSITIVITY CRP PREDICT ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY IN A GENERAL POPULATION: THE UKU LONGITUDINAL STUDY
05 May 2025	Victoria Mparnia	STUDY OF THE EFFECT OF BRADYKININ B2 RECEPTOR ACTIVATION, IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA AND CARDIOVASCULAR RISK








Date	Author	Title
06 May 2025	Stephen J. Nicholls	IMPACT OF ADJUNCTIVE LIPID-MODIFYING THERAPY IN CLEAR OUTCOMES TRIAL
06 May 2025	Madlaina Costa- Scharplatz	HOW COMMON IS ELEVATED LP(A) IN PREMATURE ASCVD PATIENTS? A REAL-WORLD STUDY USING A LARGE US ELECTRONIC HEALTH RECORD DATABASE
06 May 2025	Hyung Joon Joo	PREDICTORS OF HIGH LIPOPROTEIN(A) VARIABILITY: A MULTICENTER STUDY AND IMPLICATIONS FOR RISK STRATIFICATION
06 May 2025	Beryl B. Cummings	REAL-WORLD ANALYSIS OF THE ASSOCIATION OF REMNANT CHOLESTEROL LEVELS WITH MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
06 May 2025	Diane E. Macdougall	CHOLESTEROL TREATMENT TRENDS FROM 2014-2023 IN 3 MILLION US INDIVIDUALS WITH ASCVD: A RETROSPECTIVE COHORT ANALYSIS USING THE FAMILY HEART DATABASE
Virtual (On Demand)	Sofia Morini	UNCONVENTIONAL RISK FACTORS IN CARDIOVASCULAR DISEASES: A POPULATION BASED ITALIAN COHORT STUDY
Virtual (On Demand)	Ioannis Koutsaliaris	EPA PROMOTES ANGIOGENESIS IN OECS MORE EFFECTIVELY THAN DHA. AN IN VITRO STUDY.
Virtual (On Demand)	Muneeza Ijaz	MORTALITY TRENDS AMONG DYSLIPIDEMIC PATIENTS WITH ARRHYTHMIA: A RETROSPECTIVE ANALYSIS OF THE IMPACT OF GENDER, ETHNICITY AND GEOGRAPHY IN USA FROM 1999-2022








Date	Author	Title
05 May 2025	Veronika Todorovová	ASSOCIATION BETWEEN MALE MORTALITY AND GENETIC RISK SCORES ASSOCIATED WITH TRIGLYCERIDEMIA AND RISK OF MYOCARDIAL INFARCTION
05 May 2025	Diego Cabrera	UTILITY OF NGS IN THE GENETIC DIAGNOSIS OF HF AND SIMILAR LIPID DISORDERS: DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS
05 May 2025	Thivanka Manawadu	DOES CAROTID INTIMA MEDIA THICKNESS HAVE A ROLE IN PREDICTING GENETIC FAMILIAL HYPERCHOLESTEROLAEMIA?
05 May 2025	Drazen Perica	GENETIC VARIANTS OF FAMILIAR HYPERCHOLESTEROLEMIA - SINGLE CENTER FIRST REPORT
05 May 2025	Fouzia Sadiq	NOVEL CREB3L3 VARIANT ASSOCIATED WITH SEVERE HYPERTRIGLYCERIDEMIA
05 May 2025	Fang-I Hsieh	THE ASSOCIATION OF GENETIC POLYMORPHISMS OF UCP1-UCP3 AND THE RISK OF POOR OUTCOME AT 1-MONTH POST-STROKE AMONG ISCHEMIC STROKE PATIENTS
05 May 2025	Silvia Roda	ATP CITRATE LYASE GENE SILENCING: IMPACT ON LIPID METABOLISM OF HEPATOCYTES
05 May 2025	Claudia Monsalve-Arango	FAMILIAL CHYLOMICRONEMIA WITH REDUCED LPL ACTIVITY AND NEGATIVE GENETIC TESTING: A  CASE REPORT
05 May 2025	Juan Nogueira	A NOVEL HOMOZYGOUS VARIANT IN APOA5: A SERIAL CASES REPORTS OF FAMILIAL CHYLOMICRONEMIA SYNDROME FROM COLOMBIA








Date	Author	Title
05 May 2025	Janja Zupan	GENE EXPRESSION OF COREGULATORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN PATEINTS WITH CORONARY ARTERY DISEASE
05 May 2025	Zhi Chng Lau	DIFFERENTIAL GENE EXPRESSION ANALYSIS HIGHLIGHTS DISTINCT CORONARY ARTERY DISEASE PATHOGENESIS PATHWAYS RELATED TO TELOMERE LENGTH ATTRITION IN ARTERIAL WALL TISSUES AND GRANULOCYTES
05 May 2025	Marianne Klevmoen	CURRENT GUIDELINES RESULT IN EXTENSIVE PREGNANCY-RELATED OFF-TREATMENT TIME IN WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA
05 May 2025	Aya A. Shouma	ANALYSIS OF THE DIABETIC ARTERIAL TRANSCRIPTOME REVEALS NOVEL BIOMARKERS OF MACROVASCULAR DISEASE
05 May 2025	Daniel Gaudet	TRANSITION OF PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME FROM VOLANESORSEN TO OLEZARSEN: UPDATED INTERIM SAFETY AND PHARMACOKINETIC RESULTS
05 May 2025	Maëlle C. Jan	GENETIC SCREENING AND FUNCTIONAL ANALYSIS OF LIPA VARIANTS IN AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA
06 May 2025	David Kallend	PHASE 3 POOLED LONG-TERM SAFETY AND EFFICACY OF LERODALCIBEP IN PATIENTS WITH ASCVD, HEFH, VERY HIGH OR HIGH RISK FOR ASCVD
06 May 2025	Jonviea Chamberlain	THE EPIHEART SIGNATURE: AN EPIGENETIC BIOMARKER OF CARDIOVASCULAR DISEASE RISK
06 May 2025	Jonviea Chamberlain	CELL TYPE-SPECIFIC DIFFERENTIAL METHYLATION AND CARDIOVASCULAR RISK: INTEGRATION OF DECONVOLVED EPIGENETIC AND TRANSCRIPTOMIC SIGNALS








Date	Author	Title
06 May 2025	Samuel Gidding	HYPOALBUMINEMIA GENETIC VARIANTS ARE ASSOCIATED WITH HIGHER CHOLESTEROL LEVELS BUT NOT ATHEROSCLEROTIC HEART DISEASE
06 May 2025	Chenbo Xu	AAV GENE THERAPY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: TRANSLATIONAL STUDIES AND EARLY PHASE I TRIAL INTERIM RESULTS








Date	Author	Title
05 May 2025	Kakha Nadaraia	EFFECTIVENESS AND SAFETY OF EARLY ADMINISTRATION OF COLCHICINE IN PATIENTS WITH NON-ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION
05 May 2025	Devendra Agrawal	DIFFERENTIALLY EXPRESSED GENES IN THE REGULATION OF ECM REMODELING IN ARTERIOVENOUS FISTULA IN YUCATAN MINISWINE
05 May 2025	Ting Ting Chang	NITRIC OXIDE DONOR THERAPY IMPROVES ISCHEMIA-INDUCED NEOVASCULARIZATION IN CHRONIC KIDNEY DISEASE
05 May 2025	Tatyana Storozhenko	PROGNOSTIC VALUE OF BIOMARKERS IN ACUTE MYOCARDIAL INFARCTION WITH REDUCED GLOMERULAR FILTRATION RATE: A COMPARATIVE COHORT STUDY
05 May 2025	Hosna Elshony	SPINAL CORD ISCHEMIA SECONDARY TO AORTIC DISSECTION: CASE REPORT WITH LITERATURE REVIEW FOR DIFFERENT CLINICAL PRESENTATIONS, RISK FACTORS, RADIOLOGICAL FINDINGS, THERAPEUTIC MODALITIES, AND OUTCOME
05 May 2025	Victor Gurevich	EFFECTIVE MICROCIRCULATION AS AN ADAPTIVE FACTOR PREVENTING MYOCARDIAL ISCHEMIA IN HETEROZYGOUS HYPERCHOLESTEROLEMIA
05 May 2025	Nagaisha Nagajothi	USE OF EXTRA LONG SHEATH FOR TRANS-RADIAL CARDIAC CATHETERIZATION
05 May 2025	Panagiotis Zachos	ANTIPHOSPHOLIPID SYNDROME AND CARDIAC COMPLICATIONS
05 May 2025	Hyun-Jin Kim	EFFECT OF ESTIMATED PULSE WAVE VELOCITY ON LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE







Date	Author	Title
05 May 2025	Jan Kyselovic	ATORVASTATIN IMPROVES CRITICAL LIMB ISCHEMIA BY ENHANCING ANGIOGENESIS VIA VEGF-A, HGF, AND IGF-1 MODULATION IN BONE MARROW-DERIVED MSCS
05 May 2025	Qadeer Abdul	EVALUATION OF ALTERED ECHOCARDIOGRAPHIC PARAMETERS FOR CANCER THERAPEUTICS-RELATED  CARDIAC DYSFUNCTION IN PATIENTS WITH LYMPHOMA/LEUKEMIA AFTER ANTHRACYCLINE  CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
05 May 2025	Ibrahim Nasser	CAN ROUTINE ECHOCARDIOGRAPHIC PARAMETERS DETECT SUBTLE MYOCARDIAL DYSFUNCTION IN SARCOID PATIENTS? A META-ANALYSIS
05 May 2025	Talal Warsi	PRE-TREATMENT WITH ALLOPURINOL IN ACUTE MYOCARDIAL INFARCTION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
05 May 2025	Baojun Zhong	HIGH PLASMA MANNOSE-BINDING LECTIN (MBL) IS ASSOCIATED WITH INCREASED RISK OF HEART FAILURE AFTER AN ACUTE CORONARY SYNDROME – A PROSPECTIVE COHORT STUDY
05 May 2025	Sandra Vladimirov Sopic	TARGETED NMR METABOLOMICS REVEALS SEX-SPECIFIC MARKERS OF MYOCARDIAL INFARCTION
05 May 2025	Loukianos Rallidis	ON TREATMENT REMNANT CHOLESTEROL LEVELS ARE PREDICTIVE OF MYOCARDIAL INFARCTION AMONG PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: DATA FROM LAERTES AND STAMINA REGISTRIES
05 May 2025	Yong Fen Qi	INTERMEDIN UP-REGULATES MITOCHONDRIAL SIRT3 TO ATTENUATE AGING-ASSOCIATED CARDIAC REMODELING BY RECEPTOR-MEDIATED SIGNALING PATHWAYS
05 May 2025	Amna Arif	ANTIPLATELET AND ANTICOAGULANT COMPOUND (APAC) RESTRICTS THROMBOINFLAMMATION TO AMELIORATES MYOCARDIAL ISCHEMIA REPERFUSION INJURY








Date	Author	Title
06 May 2025	Miron Sopić	EXPLORING EPITRANSCRIPTOMIC LANDSCAPE OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN MYOCARDIAL INFARCTION
06 May 2025	Xiaowei Li	INHIBITION OF B CELL ACTIVATION BY IBRUTINIB IMPROVES CARDIAC FUNCTION IN EXPERIMENTAL MYOCARDIAL INFARCTION IN MICE
06 May 2025	Loukianos Rallidis	LIPOPROTEIN (A) LEVELS ABOVE 70 MG/DL ARE ASSOCIATED WITH MAJOR ADVERSE CARDIAC EVENTS IN SECONDARY PREVENTION: DATA FROM CALLINICUS-HELLAS REGISTRY
Virtual (On Demand)	Yimeng Wang	RELATIONSHIP BETWEEN STRESS HYPERGLYCEMIA RATIO OF ONE-YEAR MORTALITY IN PATIENTS WITH HEART FAILURE: ANALYSIS OF THE MIMIC-IV DATABASE.
Virtual (On Demand)	Diana Kiseleva	OSMOLALITY REMODELING EFFECT ON NEONATAL RAT CARDIOMYOCYTES MONOLAYERS
Virtual (On Demand)	Alyena Golubeva	NONINVASIVE PARAMETERS OF MYOCARDIAL WORK AND DIASTOLIC MYOCARDIAL FUNCTION IN THE ASSESSMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS
Virtual (On Demand)	Alyena Golubeva	THE RELATIONSHIP OF MYOCARDIAL DEFORMATION CHARACTERISTICS WITH HEART RATE  VARIABILITY IN PATIENTS WITH STEMI
Virtual (On Demand)	Tatyana Medvedeva	GRANULOCYTE COLONY STIMULATING GROWTH FACTOR (G-CSF), GRANULOCYTE-MACROPHAGE COLONY STIMULATING GROWTH FACTOR (GM-CSF) IN THE PATHOGENESIS OF HEART FAILURE IN YOUNG MEN WITH GOUT
Virtual (On Demand)	Olga Gruzdeva	SPHINGOMYELINS PROFILE OF LOCAL HEART FAT DEPOTS IN PATIENTS WITH CORONARY ARTERY DISEASE AND HEART FAILURE








Date	Author	Title
Virtual (On Demand)	Sofia Dolmatova	LEPTIN RESISTANCE IN PATIENTS WITH MYOCARDIAL INFARCTION AND ISCHEMIC HEART DISEASE
Virtual (On Demand)	Nilufar Usmonova	PSYCHOSOMATIC DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE AND ATRIAL FIBRILLATION
Virtual (On Demand)	Margarita A Sazonova	NEW MARKERS OF CORONARY HEART DISEASE WITH OLD MYOCARDIAL INFARCTION: CERTAIN VARIANTS OF RELATIVE LENGTH OF TELOMERIC REPEATS
Virtual (On Demand)	Laylo Ilxomova	THE ROLE OF MECHANICAL DISPERSION IN ASSESSING THE SEVERITY OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH CORONARY ARTERY DISEASE FOLLOWING LEFT VENTRICULAR MYOCARDIAL INFARCTION
Virtual (On Demand)	Viktoria Stepanova	ECHOCARDIOGRAPHIC PARAMETERS OF LEFT VENTRICLE REMODELING IN PATIENTS PAST MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION BEFORE AND AFTER MYOCARDIAL REVASCULARIZATION








Date	Author	Title
05 May 2025	Qadeer Abdul	IMPAIRED CARDIOVASCULAR FUNCTION ASSESSED BY DOPPLER ECHOCARDIOGRAPHY IN PATIENTS WITH MULTIPLE SCLEROSIS: A META-ANALYSIS
05 May 2025	Mahmoud Eldesouky	CLINICAL OUTCOMES OF COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY (CTCA) IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: A SINGLE-CENTRE EXPERIENCE
05 May 2025	Rafail Kotronias	COMPARATIVE EVALUATION OF PHOTON-COUNTING CCTA RELATIVE TO 3D QUANTITATIVE CORONARY ANGIOGRAPHY FOR CORONARY LUMINAL STENOSIS EVALUATION
05 May 2025	Leonardo Portolan	NON-INVASIVE PHOTON-COUNTING CCTA IMAGING OF SEVERELY CALCIFIC CORONARY ARTERY DISEASE: IS ULTRA-HIGH-RESOLUTION IMAGING THE SOLUTION?
05 May 2025	Mohammad Abusido	COMPARATIVE STUDY OF TWO DIFFERENT MIDDLE EASTERN POPULATIONS WITH CORONARY HEART DISEASE; PATIENTS WITH OVERT SYNDROMES AND PATIENTS DIAGNOSED BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY
05 May 2025	Sanghyun Park	HIGH BRACHIAL-ANKLE PULSE WAVE VELOCITY IS A RISK FACTOR FOR CARDIOVASCULAR EVENT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING INVASIVE CORONARY ANGIOGRAPHY: A MULTICENTER STUDY
05 May 2025	Arianna Toscano	CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ROLE OF NON-INVASIVE IMAGING AND TRADITIONAL RISK SCORES
05 May 2025	Spyridon Simantiris	CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN GREEK CLINICAL PRACTICE: DATA FROM A CONTEMPORARY, REAL-WORLD MULTICENTER COHORT [CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY – GREECE (COCOA-GR)]
05 May 2025	Simon Williams	DIFFERENCES IN PROTEIN CONCENTRATION BETWEEN SYSTEMIC BLOOD AND BLOOD FROM DISEASED CORONARY ARTERIES; EARLY INSIGHTS FROM THE BIOPATTERN TRIAL








Date	Author	Title
05 May 2025	Sam Fry	AUTOMATED QUANTITATIVE PLAQUE ANALYSIS FOR THE ASSESSMENT OF LARGE CCTA REGISTRY  DATASETS
06 May 2025	Paula Nogales	18FDG-PET IMAGING REVEALS GLYCOLYTIC ACTIVITY AS A MARKER OF ATHEROSCLEROTIC DISEASE ACTIVITY
06 May 2025	Ibrahim A. Nasser	SPECKLE-TRACKING ECHOCARDIOGRAPHY DETECTS EARLY CHANGES IN LEFT VENTRICULAR MYOCARDIAL DEFORMATION MECHANICS IN PATIENTS WITH SARCOIDOSIS: A META-ANALYSIS
06 May 2025	Nitish K. Behary Paray	ASSESSMENT OF SUBCLINICAL MYOCARDIAL DEFORMATION INDICES AND SPECKLE TRACKING ECHOCARDIOGRAPHY ALTERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A META-ANALYSIS
06 May 2025	Thomas Halborg	EVALUATING CORONARY ARTERY INFLAMMATION BY ANALYSING PERI-CORONARY FAT ATTENUATION INDEX SCORE: INSIGHTS FROM POST-MORTEM CCTA AND HISTOPATHOLOGY
06 May 2025	Yangyang Cheng	CORRELATION BETWEEN MYOCARDIAL MICRO-ALTERATIONS AND INTRACRANIAL ATHEROSCLEROSIS IDENTIFIED BY HR- MRI IN MIDDLE-AGED OR OVER COMMUNITY DWELLING ADULTS
Virtual (On Demand)	Toqeer Ahmed	DETECTION OF MYOCARDIAL DAMAGE IN PATIENTS WITH CARDIAC SARCOIDOSIS VERSUS EXTRACARDIAC SARCOIDOSIS USING SPECKLE TRACKING ECHOCARDIOGRAPHY: A META-ANALYSIS
Virtual (On Demand)	Alexander Vrublevsky	DISTURBANCES OF THE THORACIC AORTA BIOMECHANICS IN DEGENERATIVE CALCIFIC AORTIC VALVE STENOSIS: 2D SPECKLE-TRACKING TRANSOESOPHAGEAL ECHOCARDIOGRAPHIC ASSESSMENT
Virtual (On Demand)	Dmitriy Panfilov	THORACIC AORTA BIOMECHANICS AFTER HEMIARCH REPAIR: 2D SPECKLE-TRACKING TRANSOESOPHAGEAL ECHOCARDIOGRAPHIC ASSESSMENT







Date	Author	Title
Virtual (On Demand)	Henil Upadhyay	CT IMAGING OF SUBCLINICAL ATHEROSCLEROSIS IN LIPID CLINICS: TIME TO STOP LIVING UNDER A ROCK







Date	Author	Title
05 May 2025	Federica Fogacci	IMPACT OF TREATMENT WITH EVOLOCUMAB ON BIOMARKERS OF CHRONIC SYSTEMIC AND VASCULAR INFLAMMATION
05 May 2025	Moustafa Morsy	INFLAMMATORY MARKERS ARE ASSOCIATED WITH ISCHAEMIC STROKE AMONG INDIGENOUS  AFRICANS: THE SIREN STUDY
05 May 2025	Andisyah Putri Sekar	CLINICAL OUTCOMES OF BLEEDING AND EMBOLISM IN PATIENTS USING ANTITHROMBOTIC AND ANTI-INFLAMMATORY DRUGS: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE
05 May 2025	Fatemah Almarri	INFLAMMATION-RELATED PLASMA PHENOTYPE: A NOVEL BIOMARKER OF ATHEROSCLEROSIS
05 May 2025	Ljiljana Majnaric	FACTORS INFLUENCING VARIATIONS OF THE INFLAMMATORY MARKER NLR IN PRIMARY CARE  PATIENTS WITH T2D
05 May 2025	Ljiljana Majnaric	DIAGNOSTIC AND PROGNOSTIC RELEVANCE OF INFLAMMATORY MARKERS IN T2D PATIENTS
05 May 2025	Guyu Zeng	THE COMBINED AND MEDIATING PROGNOSTIC IMPACT OF INFLAMMATION AND STRESS HYPERGLYCEMIA IN DIABETIC AND NONDIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME
05 May 2025	Florence Ottones	PHENOTYPIC, METABOLIC, AND FUNCTIONAL CHARACTERIZATION OF EXPERIMENTAL MODELS OF FOAMY MACROPHAGES: TOWARD THERAPEUTIC RESEARCH IN ATHEROSCLEROSIS
05 May 2025	Miran Šebeštjen	INFLUENCE OF PCSK9 INHIBITORS ON GENE EXPRESSION OF INFLAMMATION AND HEMOSTASIS PARAMETERS IN PATIENTS WITH CORONARY ARTERY DISEASE







Date	Author	Title
05 May 2025	Nikolai Orekhov	IMPROVING PROGNOSTIC SIGNIFICANCE OF LOW-DENSITY LIPOPROTEIN-CONTAINING CIRCULATING IMMUNE COMPLEXES IN ATHEROSCLEROSIS
05 May 2025	Samuel Sherratt	ADDITION OF EICOSAPENTAENOIC ACID (EPA) TO A GLP-1 AGONIST INCREASED EXPRESSION OF AN ENDOTHELIAL ANTIOXIDANT RESPONSE ELEMENT (ARE) PROTEIN IN A SYNERGISTIC FASHION DURING INFLAMMATION
05 May 2025	Samuel Sherratt	EICOSAPENTAENOIC ACID (EPA) AND A GLP-1 AGONIST CAUSED SYNERGISTIC CHANGES IN PROTEIN EXPRESSION AND MEDIATORS OF ENDOTHELIAL ENDOPLASMIC RETICULUM FUNCTION DURING INFLAMMATION
05 May 2025	Xiaohan Zhang	MODULATING PENTOSE PHOSPHATE PATHWAY TO ATTENUATE VASCULAR ENDOTHELIAL INFLAMMATION
05 May 2025	Tuva Dahl	M6A METHYLATION DYNAMICS IN STEMI: IL-6 INHIBITION AND IMMUNE MODULATION
05 May 2025	Ingrid E. Dumitriu	FRACTALKINE RECEPTOR CX3CR1 REGULATES MIGRATION OF CD4CD28NULL T CELLS IN HIGH-RISK <u>ACUTE CORONARY SYNDROME PATIENTS</u>
05 May 2025	Ciarán Kennedy	TIPPING THE BALANCE: INVESTIGATING THE POTENTIAL OF THE SPECIALISED PRO-RESOLVING MEDIATOR LIPOXIN-A4 TO MODULATE THE INFLAMMATORY LANDSCAPE IN ATHEROSCLEROSIS.
05 May 2025	Agnė Liuizė	MARKERS OF INFLAMMATION, AS MEASURED BY A COMPLETE BLOOD COUNT, ARE ASSOCIATED WITH CORONARY ATHEROSCLEROSIS AND REFLECT ITS SEVERITY
05 May 2025	Neil Macritchie	DEFICIENCY IN THE INFLAMMATORY CHEMOKINE RECEPTORS 1,2,3 AND 5 ATTENUATES ATHEROSCLEROSIS IN MICE WHILE REDUCING AORTIC INFLAMMATORY MONOCYTE-MACROPHAGE CONTENT








Date	Author	Title
05 May 2025	Tomasz Mikolajczyk	ROLE OF ATYPICAL CHEMOKINE RECEPTOR 2 IN HYPERTENSION.
05 May 2025	Janneke W.C.M. Mulder	INSIGHTS INTO THE ROLE OF TRIGLYCERIDES AND T CELLS IN CARDIOVASCULAR RISK: T CELLS OF PATIENTS WITH MODERATE HYPERTRIGLYCERIDEMIA HAVE A PRO-INFLAMMATORY TRANSCRIPTOMIC PROFILE
05 May 2025	Goo Taeg Oh	PCSK9 DEFICIENCY MITIGATES CARDIAC INFLAMMATION AFTER MYOCARDIAL INFARCTION VIA  UPREGULATION OF ATRIAL NATRIURETIC PEPTIDE
05 May 2025	Alexander N Orekhov	GENE AND EPIGENETIC REGULATION IN VIOLATION OF THE INFLAMMATORY RESPONSE IN ATHEROSCLEROSIS
05 May 2025	Maike Schneider	PHARMACOLOGICAL DOSE OF ATORVASTATIN INDUCES INFLAMMASOME ACTIVATION IN HUMAN MONOCYTES
05 May 2025	Barbara Šernek	EFFECT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS ON VASCULAR WALL INFLAMMATION PARAMETERS
05 May 2025	Vasily Sukhorukov	IMMUNE RESPONSE IN MONOCYTE-LIKE CYBRIDS WITH ATHEROSCLEROSIS-RELATED  MITOCHONDRIAL MUTATIONS
05 May 2025	Eveline Van Doorn	SEX-SPECIFIC DIFFERENCES IN INNATE IMMUNE PHENOTYPE IN AORTIC STENOSIS
05 May 2025	Yuzhe Weng	LOW-DOSE IL-2 PROMOTES A TREG-DEPENDENT B CELL IMMUNOGLOBULIN CLASS SWITCH IN  ATHEROSCLEROSIS








Date	Author	Title
05 May 2025	Daria Borodko	CHRONIC INFLAMMATORY DISEASE: WHO IS RESPONSIBLE FOR NON-TOLERANT REACTION?
05 May 2025	Natalie Fournier	EICOSAPENTAENOIC ACID (EPA) REDUCES ABCA1 AND SR-BI CHOLESTEROL EFFLUX PATHWAYS FROM CHOLESTEROL-LOADED HUMAN THP-1 MACROPHAGES WITHOUT AFFECTING THE CELL PHENOTYPE
05 May 2025	Raquel Griñán	MIR-30D-5P CONTROLS HYPERHOMOCYSTEINEMIA-RELATED ATHEROSCLEROSIS THROUGH THE REGULATION OF TIMP3 AND MMP9








Date	Author	Title
05 May 2025	Alessia Cipollone	EFFICACY AND SAFETY OF MONOCLONAL ANTIBODIES AGAINST PCSK9I: REAL LIFE DATA
05 May 2025	Luka Prgomet	CLINICAL INERTIA IN DYSLIPIDEMIA AND HYPERTENSION TREATMENT - RESULTS FROM THE NATIONWIDE STUDY EHUH-2 (CROATIA) - PRELIMINARY FINDINGS
05 May 2025	Mircea-Vasile Milaciu	ARTERIAL STIFFNESS MEASUREMENTS IN A VULNERABLE ROMANIAN POPULATION: PARTIAL RESULTS FROM THE MELVIN PROJECT
05 May 2025	Fatema Abdullah	HIGH-FAT DIET INTENSIFY RENAL FIBROSIS INDEPENDENT OF HYPERTENSION THROUGH TGFB AND PDGF SIGNALING: RESULTS FROM HYPERTENSIVE RAT STRAINS
05 May 2025	John Kastelein	EFFICACY AND SAFETY OF COMBINATION OBICETRAPIB WITH MODERATE-DOSE STATINS
05 May 2025	Ayoub Salehi	STUDYING THE EFFICACY OF LOW DOSE COLCHICINE ON CLINICAL OUTCOMES OF PATIENTS WITH STEMI: A RANDOMIZED CONTROLLED TRIAL.
05 May 2025	Luke Gamon	SPATIAL PROTEOMICS OF THE HUMAN ATHEROSCLEROTIC MICROENVIRONMENT REVEALS HETEROGENEITY IN INTRA-PLAQUE PROTEOMES AND EXTRACELLULAR MATRIX REMODELING
05 May 2025	Aarif Khakoo	POTENT, DURABLE, AND SAFE LDLC REDUCTION IN NON-HUMAN PRIMATES WITH A NOVEL CRISPR-BASED EPIGENETIC SILENCER AT THERAPEUTICALLY RELEVANT DOSES
05 May 2025	Xiao-Yu Tian	OSCILLATORY SHEAR STRESS REGULATES STRESS GRANULE DYNAMICS AND ITS INTERACTION WITH PPARD DURING ATHEROGENESIS







Date	Author	Title
05 May 2025	Sander Eens	DOXORUBICIN PROMOTES ATHEROSCLEROSIS IN AN APOLIPOPROTEIN E-DEFICIENT MOUSE MODEL, POTENTIALLY ASSOCIATED WITH SERPINA3N
06 May 2025	Laura Alonso-Herranz	SMAD7 DELETION IN SMOOTH MUSCLE CELLS PROMOTES THE CONTRACTILE PHENOTYPE AND RESULTS IN MORE STABLE ATHEROSCLEROTIC PLAQUES
06 May 2025	Daniel M. Clemens	A PHASE 1 TRIAL OF UDP-003, A THERAPEUTIC TO REVERSE ATHEROSCLEROSIS BY THE SPECIFIC REMOVAL OF 7-KETOCHOLESTEROL
7 May 2025	Brian A. Ference	SAFETY AND EFFICACY OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION: FROM GENETICS TO OUTCOME TRIALS





Key Industry Sponsored Sessions Information





# EAS 2025 Key Industry Sponsored Sessions Information (1/3)

Date	Sponsor	Title
04 May 2025	Menarini Group	NEW TREATMENT OPTIONS IN DYSLIPIDEMIA, FROM BASIC SCIENCE TO CLINICAL EVIDENCE
		UNMET NEEDS IN LIPIDOLOGY
		THE BIOLOGICAL BASIS OF CETP INHIBITION
		POTENTIAL ROLE OF CETPI IN CARDIOMETABOLIC RISK
05 May 2025	Ultragenyx	OPTIMIZING THE DIAGNOSIS AND TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH)
		HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): AETIOLOGY, PRESENTATION AND DIAGNOSIS THROUGH THE LENS OF THE HICC REGISTRY – WHERE ARE THE 'MISSING' PATIENTS?
		EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOFH: A REVIEW OF THE CLINICAL DATA IN ADULT, ADOLESCENT AND PAEDIATRIC PATIENTS





### EAS 2025 Key Industry Sponsored Sessions Information (2/3)

Date	Sponsor	Title
05 May 2025	Ultragenyx	CLINICAL EXPERIENCE WITH EVINACUMAB AT EVELINA LONDON CHILDREN'S HOSPITAL
06 May 2025	Amarin	CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL: ARE WE STILL MISSING THE LINK?
		CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL IN REDUCE-IT
		EPA'S MECHANISM OF ACTION: CONNECTING THE DOTS
		BEYOND GUIDELINES - INTEGRATING EMERGING EVIDENCE
06 May 2025	Daiichi Sankyo	ADVANCING LIPID MANAGEMENT: INSIGHTS FROM REAL-WORLD EVIDENCE AND COMBINATION THERAPY TRIALS
		TOWARDS GOAL ATTAINMENT: EXPLORING ORAL LIPID-LOWERING STRATEGIES FOR HIGH-RISK PATIENTS






# EAS 2025 Key Industry Sponsored Sessions Information (3/3)

Date	Sponsor	Title
06 May 2025	Daiichi Sankyo	COMPARATIVE REAL-WORLD OUTCOMES ACROSS EUROPEAN COUNTRIES: INSIGHTS FROM THE MILOS STUDY
06 May 2025	Chiesi	GETTING TO THE HEART OF THE MATTER: OPTIMISING LONG-TERM PATIENT OUTCOMES IN ADULT HOFH
		USING REAL-WORLD EVIDENCE TO BETTER UNDERSTAND DISEASE BURDEN IN HOFH
		TREATING TO TARGET: ACHIEVING LDL-C GOALS IN HOFH
		PATIENTS AT THE HEART OF UK HOFH CARE





### Noteworthy AI / ML presentations at EAS 2025







### Themes from key AI / ML presentations at EAS 2025 (1/2)

- At EAS 2025, AI and machine learning are transforming cardiovascular care through advanced risk stratification, precision imaging, and personalized prevention—leveraging real-world data, deep learning models, and digital health platforms to optimize patient outcomes
- Check out the key AI / ML themes at EAS 2025 below:
- Risk Stratification and Predictive Modeling:
  - AI was used to predict long-term cardiovascular risk in the ATTICA study (20-year data) and for dyslipidemia detection, enabling proactive patient segmentation and therapy planning
- AI-Driven Imaging Enhancements:
  - Deep learning models improved segmentation of coronary and perivascular anatomy, enhancing diagnostic accuracy in CTA and guiding treatment in stable angina using AIbased FAI scoring
- Machine Learning in Coronary Disease Diagnosis:
  - AI tools predicted coronary artery stenosis and identified lesions in angiography, reducing unnecessary procedures and supporting cost-effective clinical decision-making



2025



### Themes from key AI / ML presentations at EAS 2025 (2/2)

### Personalized Prevention Through Digital Health:

 AI-powered platforms and digital health solutions enabled tailored prevention strategies, leveraging real-world data and omics profiling for individualized cardiovascular risk reduction

#### AI in Multimodal Disease Characterization:

 Studies applied AI to phenotype atherosclerosis, analyze coronary plaque volume, and assess cardio-atherogenic risk in early Parkinson's using radiological and biochemical variables





Noteworthy AI / ML presentations at EAS 2025



# Notable Presentations At EAS 2025 AI / ML (1/2)



Date	Author	Title Title
05 May 2025	Anastassia Anastassopoulou	ARTIFICIAL INTELLIGENCE-POWERED APPROACHES FOR REAL-WORLD EVIDENCE RESEARCH CHALLENGES IN LIPID MANAGEMENT: A NARRATIVE REVIEW
05 May 2025	Ikboljon Sobirov	A NOVEL DEEP LEARNING MODEL FOR ENHANCED SEGMENTATION OF INTERNAL MAMMARY ARTERY, AORTA AND THEIR PERIVASCULAR REGIONS
05 May 2025	Jamol Uzokov	THE ROLE OF ARTIFICIAL INTELLIGENCE IN IDENTIFYING CORONARY ARTERY LESIONS IN CORONARY  ANGIOGRAPHY
05 May 2025	Nerea Sanfeliu Garces	THE UTILITY OF FAT ATTENUATION INDEX (FAI) AND AI-SCORING IN CHANGING MANAGEMENT OF STABLE ANGINA: A RETROSPECTIVE ANALYSIS
05 May 2025	Nadiia Demikhova	ASSESSMENT OF RISK FACTORS DURING CARDIOSURGICAL INTERVENTIONS USING ARTIFICIAL CIRCULATION
05 May 2025	Minkyung Lee	PREDICTION OF DYSLIPIDEMIA USING MACHINE LEARNING TECHNIQUES
05 May 2025	Myra Tilney	CONTEXTUAL CO-DESIGN OF A CASCADE TESTING APPROACH IN FH: QUALITATIVE STUDY OF STAKEHOLDER PERSPECTIVES TO INFORM COMMUNICATION STRATEGY IN A CHANGING DIGITAL ENVIRONMENT
05 May 2025	Frank Annie	COMPARISON OF CORONARY PLAQUE VOLUME IN A HIGH-RISK POPULATION USING AI-BASED  QUANTITATIVE CORONARY PLAQUE ANALYSIS
05 May 2025	John Deanfield	DIGITAL HEALTH SOLUTIONS FOR PERSONALISED PREVENTION



# Notable Presentations At EAS 2025 AI / ML (2/2)



Date	Author	Title Title
05 May 2025	Kenneth Chan	NOVEL AI TECHNOLOGY TO QUANTIFY CORONARY INFLAMMATION AND CARDIOVASCULAR RISK WITH ROUTINE CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY: A COST-EFFECTIVENESS ANALYSIS
05 May 2025	Andreas Leiherer	PREDICTING CORONARY ARTERY STENOSIS USING MACHINE LEARNING TO REDUCE UNNECESSARY  ANGIOGRAPHIES
06 May 2025	Calum Macrae	USING AI TO UTILISE DIGITAL INFORMATION IN CLINICAL PRACTICE
06 May 2025	Fotios Barkas	PREDICTING LONG-TERM CARDIOVASCULAR RISK USING MACHINE LEARNING: 20-YEAR DATA FROM THE ATTICA STUDY
06 May 2025	Joseph Wu	STEM CELLS, GENOMICS, AND AI FOR DRUG DISCOVERY
07 May 2025	Thomas F. Luscher	WILL AI CURE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
07 May 2025	Ron Blankstein	ATHEROSCLEROSIS PHENOTYPING USING ARTIFICIAL INTELLIGENCE: IMPLICATIONS FOR IMAGING
07 May 2025	Manuel Mayr	GAIN UNPRECEDENTED INSIGHTS INTO CVD WITH THE LATEST -OMICS TECHNOLOGIES USING GENERATIVE AI
Virtual	Esra Demir Unal	CARDIO-ATHEROGENIC RISK ANALYSIS IN EARLY-STAGE IDIOPATHIC PARKINSON'S DISEASE USING MACHINE LEARNING MODELING METHODS BASED ON RADIOLOGICAL AND BIOCHEMICAL VARIABLES



### Strategic Insights and Strategy Development is our focus

